Schellenberg Wittmer: Bioventure in Series C financing round

Schellenberg Wittmer advised Bioventure Club Deal Nine & Co KG in a Series C financing round of the Swiss Aphaia companies, which are clinical-stage pharmaceutical companies that have developed proprietary treatment methods targeting obesity and related metabolic diseases.

The Schellenberg Wittmer team comprised Oliver Triebold (pictured), Elia Claude Schunck and Seraina Zuber (all corporate / M&A).